[go: up one dir, main page]

ZA200700553B - Galenic applications of self-emulsifying mixtures of lipidic excipients - Google Patents

Galenic applications of self-emulsifying mixtures of lipidic excipients Download PDF

Info

Publication number
ZA200700553B
ZA200700553B ZA200700553A ZA200700553A ZA200700553B ZA 200700553 B ZA200700553 B ZA 200700553B ZA 200700553 A ZA200700553 A ZA 200700553A ZA 200700553 A ZA200700553 A ZA 200700553A ZA 200700553 B ZA200700553 B ZA 200700553B
Authority
ZA
South Africa
Prior art keywords
mixture
excipients
proportions
active principle
application according
Prior art date
Application number
ZA200700553A
Other languages
English (en)
Inventor
Pachot Jean
Segot Chicq Serge
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ZA200700553B publication Critical patent/ZA200700553B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200700553A 2004-07-27 2007-01-19 Galenic applications of self-emulsifying mixtures of lipidic excipients ZA200700553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408269A FR2873585B1 (fr) 2004-07-27 2004-07-27 Nouvelles formulations galeniques de principes actifs

Publications (1)

Publication Number Publication Date
ZA200700553B true ZA200700553B (en) 2008-05-28

Family

ID=34951660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700553A ZA200700553B (en) 2004-07-27 2007-01-19 Galenic applications of self-emulsifying mixtures of lipidic excipients

Country Status (18)

Country Link
US (2) US20080193519A1 (fr)
EP (1) EP1771154A1 (fr)
JP (1) JP2008508191A (fr)
KR (1) KR20070046819A (fr)
CN (1) CN101001608A (fr)
AU (1) AU2005273839A1 (fr)
BR (1) BRPI0513622A (fr)
CA (1) CA2579449A1 (fr)
FR (1) FR2873585B1 (fr)
IL (1) IL180714A0 (fr)
MA (1) MA28748B1 (fr)
MX (1) MX2007001141A (fr)
NO (1) NO20070354L (fr)
NZ (1) NZ552715A (fr)
RU (1) RU2381789C2 (fr)
TW (1) TW200616640A (fr)
WO (1) WO2006018501A1 (fr)
ZA (1) ZA200700553B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867323A1 (fr) * 2006-06-13 2007-12-19 Farmatron Ltd. Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques
ES2551125T3 (es) * 2007-08-21 2015-11-16 Basilea Pharmaceutica Ag Composición antifúngica
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (fr) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Preparations et therapies de substitution pour hormonotherapie naturelle combinee
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2019396217A1 (en) * 2018-12-10 2021-07-08 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
CN114246827B (zh) * 2022-01-04 2023-04-11 中山大学 一种鱼油微乳制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
FR2710535B1 (fr) * 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
EP0933367A1 (fr) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Dérivés d'acylguanidine comme inhibiteurs de résorbtion osseuse et comme antagonistes de récepteur vitronectine
HUP0100520A3 (en) * 1998-01-23 2002-11-28 Genentech Inc Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CN100341485C (zh) * 1998-04-01 2007-10-10 斯凯伊药品加拿大公司 抗癌组合物
EP1015046A2 (fr) * 1998-07-14 2000-07-05 Em Industries, Inc. Systemes d'apport de medicaments par microdispersion
GB0003685D0 (en) * 2000-02-17 2000-04-05 Univ Cardiff Sensitisation of cellular material
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1506188B1 (fr) * 2002-05-14 2009-02-25 Xenova Limited Procede de preparation d'un hydrate de derive d'acide anthranilique

Also Published As

Publication number Publication date
NZ552715A (en) 2010-12-24
JP2008508191A (ja) 2008-03-21
NO20070354L (no) 2007-04-17
TW200616640A (en) 2006-06-01
CN101001608A (zh) 2007-07-18
WO2006018501A1 (fr) 2006-02-23
RU2007107199A (ru) 2008-09-10
IL180714A0 (en) 2007-06-03
US20080193519A1 (en) 2008-08-14
EP1771154A1 (fr) 2007-04-11
MX2007001141A (es) 2007-04-19
MA28748B1 (fr) 2007-07-02
RU2381789C2 (ru) 2010-02-20
WO2006018501A8 (fr) 2007-03-01
FR2873585B1 (fr) 2006-11-17
US20110104268A1 (en) 2011-05-05
AU2005273839A1 (en) 2006-02-23
CA2579449A1 (fr) 2006-02-23
FR2873585A1 (fr) 2006-02-03
BRPI0513622A (pt) 2008-05-13
KR20070046819A (ko) 2007-05-03

Similar Documents

Publication Publication Date Title
ZA200700553B (en) Galenic applications of self-emulsifying mixtures of lipidic excipients
Jo et al. Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems
Gonçalves et al. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide
Yu et al. Supersaturated polymeric micelles for oral cyclosporine A delivery
KR101759750B1 (ko) 친수성 약물의 자가 미세-유화 경구용 약제 조성물 및 이의 제조 방법
AU2016245984B2 (en) Self-emulsifying formulations of DIM-related indoles
Patel et al. Novel drug delivery approach via self-microemulsifying drug delivery system for enhancing oral bioavailability of asenapine maleate: optimization, characterization, cell uptake, and in vivo pharmacokinetic studies
Khalid et al. Nano-sized droplets of self-emulsifying system for enhancing oral bioavailability of chemotherapeutic agent VP-16 in rats: A nano lipid carrier for BCS class IV drugs
Benival et al. In situ lipidization as a new approach for the design of a self microemulsifying drug delivery system (SMEDDS) of doxorubicin hydrochloride for oral administration
Kogan et al. Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions
KR20100064370A (ko) 항균 조성물
WO2008030524A2 (fr) Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp
Chudasama et al. A novel lipid-based oral drug delivery system of nevirapine
WO2013103668A1 (fr) Formulations pour une biodisponibilité augmentée de zanamivir
US6770292B2 (en) Pharmaceutical compositions for oral administration
Sonawale et al. Solubility enhancement of lipophilic drugs-solid self micro-emulsifying drug delivery system
Carli et al. Ubidecarenone nanoemulsified composite systems
KR101608178B1 (ko) 자가 미세유화 약물전달 시스템을 이용한 아토르바스타틴 칼슘의 경구 투여용 약제 조성물
HK1103024A (en) Galenic applications of self-emulsifying mixtures of lipidic excipients
KR102765173B1 (ko) 톨밥탄을 포함하는 자가 유화 약물 전달 시스템 조성물
CN105708797A (zh) 一种取代桂皮酰胺衍生物的自乳化载药系统
Yahaya et al. Piroxicam-loaded self-emulsifying drug delivery system
Li et al. 12.2 Self-Emulsifying Drug Delivery System (SEDDS): Enhancing the Oral Absorption of Lipophilic Compounds
WO2024165166A1 (fr) Système d'émulsification huile dans l'eau à base de cannabinoïdes pour administration orale ciblant des récepteurs endocannabinoïdes
Jin et al. Development of self-microemulsifying drug delivery system for enhancing the bioavailability of atorvastatin